Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients.
- Author:
Xiao-you LIU
1
;
Li-xin YU
;
Shao-jie FU
;
Jian XU
;
Chuan-fu DU
;
Wen-feng DENG
;
Yi-bin WANG
;
Gui-rong YE
;
Yan-xuan ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Carrier State; physiopathology; Cyclosporine; administration & dosage; adverse effects; pharmacology; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Hepatitis B Surface Antigens; metabolism; Hepatitis B virus; Humans; Kidney Transplantation; adverse effects; Liver; drug effects; physiology; Male; Middle Aged; Tacrolimus; administration & dosage; adverse effects; pharmacology; Young Adult
- From: Journal of Southern Medical University 2007;27(7):1090-1092
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the long-term effect and safety of tacrolimus (FK506) and cyclosporine (CsA) in kidney transplant (KT) recipients carrying hepatitis B Virus(HBV).
METHODSA total of 109 patients with HBV were randomized into FK506 group (52 cases) and CsA group (57 cases) after KT, and a 2-year-long follow-up of the patients was conducted to record the patient and graft survival, incidence of acute graft rejection and postoperative liver function.
RESULTSThe 2-year patient/graft survival was 86.0%/73.7% and 94.2%/90.3% in CsA and FK506 groups, respectively (P<0.05), with incidence of acute rejection of 10.5% and 9.6% (P>0.05), and rate of abnormal liver function of 26.3% and 15.4% (P<0.05), respectively. Eight patients (14.4%) in CsA group required a drug conversion but none in FK506 group. The drug conversion resulted in significant reduction of ALT/AST level from 255.13+/-31.38/201.88+/-21.25 U/L to 31.25+/-11.50/25.13+/-9.68 U/L (P<0.01).
CONCLUSIONFor HBV-carrying renal transplant recipients, FK506 as the primary choice of immunosuppressant can be more effective and safer than CsA.
